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Abstract: Transplant recipients are at high risk of infections
caused by multidrug resistant microorganisms. Due to the limited thera-
peutic options, innovative antimicrobial combinations against carbape-
nem-resistant Enterobacteriaceae causing severe infections are necessary.
A 61-year-old woman with a history of congenital solitary kidney
underwent renal transplantation. The postoperative course was compli-
cated by nosocomial pneumonia due to Stenotrophomonas maltophilia and
pan-sensitive Escherichia coli, successfully treated with antimicrobial
therapy. On postoperative day 22, diagnosis of surgical site infection
and nosocomial pneumonia with concomitant bacteremia due to a Kle-
bisella pneumoniae carbapenemase-producerE coliwasmade. The patient
was treated with the double-carbapenem regimen (high dose of merope-
nem plus ertapenem) and a potent synergistic and bactericidal activity of
this un-conventional therapeutic strategy was observed in vitro. Despite a
microbiological response with prompt negativity of blood cultures, the
patient faced a worse outcome because of severe hemorrhagic shock.
The double-carbapenem regimen might be considered as a rescue
therapy in those subjects, including transplant recipients, in whom
previous antimicrobial combinations failed or when colistin use might
be discouraged. Performing in vitro synergy testing should be strongly
encouraged in cases of infections caused by pan-drug resistant strains,
especially in high-risk patients.
(Medicine 95(7):e2243)
Abbreviations: BAL = bronchoalveolar lavage, BMD = broth
macrodilution method, BP = blood pressure, BSI = bloodstream
infection, BUN = blood urea nitrogen, CMV = cytomegalovirus,
CR = carbapenem resistant, CRE = carbapenem-resistant
Enterobacteriaceae, CRP = C-reactive protein, CT = computed
tomography, dNTP = deoxynucleotide, ERT = ertapenem, ESBLs =
extended spectrum beta-lactamases, ESR = erythrocyte
sedimentation rate, HR = heart rate, KPC = Klebsiella
pneumoniae carbapenemase, MDR = multidrug resistant, MEM =
meropenem, MICs = minimal inhibitory concentrations, TMP/
SMX = trimethoprim/sulfamethoxazole, WBC = white blood
count.
INTRODUCTION
T he emergence and global spread of infections caused bycarbapenem-resistant Enterobacteriaceae (CRE) are of
great concern worldwide because they are associated with high
mortality rates.1,2
Resistance to carbapenems is mainly mediated by 2 mech-
anisms: production of extended spectrum beta-lactamases com-
bined with porin loss or production of carbapenem-hydrolyzing
enzymes, namely carbapenemases.3
In the presence of carbapenemases, carbapenems at stan-
dard dosage might be ineffective; thus, polymixin-based anti-
microbial combinations have emerged as the milestone of CRE
treatment.4 However, increasing rates of polymixin resistance
have been recently reported.5
In this setting, an innovative approach based on double-
carbapenem combination (ertapenem [ERT] followed by high
dose of meropenem [MEM]) has been shown to be effective
against Klebsiella pneumoniae carbapenemase (KPC)-producer
K pneumoniae, which represents the most common CRE
reported in the literature.6–9
Given extensive healthcare contact before and after trans-
plant and the need for lifelong immunosuppression, transplant
patients are vulnerable to several infections, including those
caused by multidrug resistant (MDR) organisms.10
The risk of infection after transplantation changes over
time and is a function of the state of immunosuppression.11
Meanwhile, patients waiting for transplantation might become
colonized with nosocomial microorganisms and eventually
develop systemic infections due to these challenging pathogens
early after transplantation.11
Editor: Carlos G. Astete.
Received: August 1, 2015; revised: October 13, 2015; accepted: November
13, 2015.
From the Department of Public Health and Infectious Diseases, Sapienza
University of Rome (AO, AC, FG, AD, MDA, GF, GR, MI, CMM, MTM,
VV) and Department of Experimental Medicine and Biochemical Sciences,
University of Rome Tor Vergata (MF), Rome, Italy.
Correspondence: Alessandra Oliva, Department of Public Health and
Infectious Diseases, Sapienza University of Rome, Rome, Italy (e-mail:
alessandra.oliva@uniroma1.it).
Concept/design of the study: AO; data analysis/interpretation: AO; labora-
tory experiments: AC, MF, MDA; data collection: AD, FG, GF, MI, GR;
drafting article: AO; and critical revision of the article: CMM, MTM,
VV.
This work was supported by a grant of Sapienza University of Rome, 2014
(No. 284 C26N14S7RB).
The authors have no conflicts of interest to disclose.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the Creative Commons
Attribution License 4.0, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000002243
Medicine®
CLINICAL CASE REPORT
Medicine ! Volume 95, Number 7, February 2016 www.md-journal.com | 1
Herein, we describe a case of bloodstream infection (BSI)
caused by a KPC-producer Escherichia coli in a renal transplant
patient treated with the double-carbapenem regimen.
CASE REPORT
A 61-year-old woman with a history of congenital solitary
kidney underwent hemodialysis because of end-stage renal
failure in 2004. In July 2014, she underwent deceased donor
renal transplantation. Simultaneously, a double-pigtail stent
was placed and an endoarterectomy of the left iliac artery
was performed because of severe stenosis. The postoperatory
course was complicated by peri-renal lymphocele and bleeding
of the left iliac artery. Immuno-suppressive therapy with tacro-
limus was started and its serum concentration was regularly
measured. On postoperative day 10, the patient developed fever
(T 38.58C), chills, and dyspnea, with pain on palpation in the
lower abdominal quadrants. A chest X-ray showed the presence
of bilateral pulmonary consolidations and culture of bronch-
oalveolar lavage (BAL) grew Stenotrophomonas maltophilia
and a pan-sensitive E coli. An abdominal computed tomography
scan displayed a prevesical hematoma (9" 5" 7 cm) requiring
drainage placement. Cytomegalovirus (CMV)-DNA was
44,400 copies/mL (detection limit<200 copies/mL). According
to creatinine clearance (37mL/min), a postantibiogram anti-
microbial therapy consisting of MEM 1g every 12 h, trimetho-
prim/sulfamethoxazole (TMP/SMX) 320/1600mg divided
every 8 h and levofloxacin 750mg every 48 h was started, with
clinical (defervescence) and radiological (disappearance of
pulmonary consolidations) responses. Furthermore, intravenous
therapy with ganciclovir 150mg every 24 h was started, with a
prompt undetectability of CMV viremia.
However, on postoperative day 22 the patient became again
febrile (T 39.08C).At the physical examination, the patientwas in
poor condition, obtunded. White blood cells were 6820 cells/
mmc (reference range 4000–10,000 cells/mmc; neutrophils, N
86%, reference range 40–70%), blood urea nitrogen (BUN)
52.7mg/dL (reference range 12–25mg/dL), creatinine 1.4mg/
dL (reference range 0.4–1.0mg/dL), C-reactive protein (CRP)
84,000mg/L (reference range 0–6000mg/L), and erythrocyte
sedimentation rate (ESR) 72mm/h (reference range 0–20mm/
h). A chest X-ray showed a new consolidation in the left
pulmonary lobe. Purulent discharge was present at the site of
the recent abdominal drainage placement. Urine culture was
sterile whereas blood (n¼ 2), BAL, and abdominal drainage
cultures grew carbapenem-resistant (CR) E coli (Figure 1A).
Thus, a diagnosis of surgical site infection and nosocomial
pneumonia with concomitant bacteremia due to an MDR E coli
was made. Despite the strain was sensitive to both aminoglyco-
sides and colistin, the patient was considered to be at high risk of
antibiotic-induced nephrotoxicity. Thus, in accordance to crea-
tinine clearance (32mL/min), antimicrobial treatment with ERT
500mg every 24h (1-h infusion) followed by high dose of MEM
(2g every 12 h, 3-h infusion) was started, in the absence of
adverse effects. Considering that the administration of the
double-carbapenem regimen has not been included in the clinical
recommendation so far, thepatient gave informedwritten consent
for this unconventional therapeutic approach; thus, ethical
approval was not necessary.
FIGURE 1. (A) MICs distribution of KPC Escherichia coli by VITEK-2 system. Values in brackets refer to MIC determination by broth
macrodilutionmethod (BMD). (B) Time–kill studies for ertapenem,meropenem, and ertapenemplusmeropenem against KPC E coli. The
horizontal line represents a reduction of 3 log10CFU/mL compared with the initial bacterial count. Bactericidal activity was defined as a
$3-log10CFU/mL reduction of the initial bacterial count at each time point whereas synergy was defined as a$2-log10 decrease in CFU/
mL between the combinations and its most active constituent after 24h. ERT ¼ ertapenem, GC ¼ growth control, KPC ¼ Klebsiella
pneumoniae carbapenemase, MEM ¼ meropenem, MIC ¼ minimal inhibitory concentration, TMP/SMX ¼ trimethoprim/sulfamethox-
azole.
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After 96 h of such therapy, the patient became afebrile and
the general conditions improved. Blood (n¼ 3) and drainage
cultures were sterile. However, a mechanical obstruction of the
double pigtail stent and a leakage at the level of anastomosis
between bladder and left ureter were then observed. Creatinine
increased to 2.4mg/dL, BUN was 78.6mg/dL, and a percuta-
neous nephrostomy was required. Three days later the patient
suddenly worsened, blood pressure was 70/40 mm Hg, heart
rate (HR) 130 per min, respiratory rate 35 beats/min, red blood
cells 2,900,000 cells/mmc (reference range 4,000,000–
5,400,000 cells/mmc), and hemoglobin 6.5 g/dL (reference
range 11–14 g/dL). A radiological examination showed a mas-
sive bleeding at the level of surgical anastomosis. Despite a
prompt vasopressor and inotropic support, the patient died
(Figure 2).
Minimal inhibitory concentrations (MICs) of ERT and
MEM were determined by broth macrodilution method
(BMD) in cation-adjusted Mueller–Hinton broth.12
Diagnostic disks were used for the phenotypic determi-
nation of carbapenemases.13 For the molecular analysis, DNA
was extracted from 1 colony of a fresh culture and then eluted in
100mL of elution buffer (Qiagen, Milan, Italy). For amplifica-
tion, the lyophilized PCR mix STATNAT DNA-Mix (Sentinel
Diagnostics Robert Koch, Milan, Italy) containing 3.0mM
MgCl2, 0.8mM each deoxynucleotide (dNTP), 2 U of hot-start
Taq DNA polymerase, and reaction buffer was used. The mix
was resuspended with 1mL of the primer and probe mix and
1mL of extracted DNA, with a final volume of 20mL. The
amplification was performed using a CFX 96 Real-Time Sys-
tem (Bio-Rad Laboratories, Marnes La Coquette, France).14
Furthermore, the activity of MEM and ERT, alone and in
combination, was investigated by time-kill studies using an
initial inoculum of %5 " 105CFU/mL. At 2, 4, 6, 8 and 24 h
time points, the number of CFU was counted. The following
concentrations were used: 1" MIC ERT, 1" MIC MEM, 2"
MIC MEM, 0.5"MIC ERT þ 0.5"MIC MEM, 1"MIC ERT
þ 0.5" MIC MEM, 1" MIC ERT þ 1" MIC MEM, and 1"
MIC ERT þ 2" MIC MEM. Bactericidal activity was defined
as a$3-log10CFU/mL reduction of the initial bacterial count at
each time point whereas synergy was defined as a $2-log10
decrease in CFU/mL between the combinations and its most
active constituent after 24 h.
E coli MICs were 16 and 32mg/mL for ERT and MEM,
respectively. Phenotypic and molecular analyses showed that
the strain was a KPC-producer.
In the killing curves, despite an initial reduction in log
CFU/mL a regrowth at 24 h was observed for 1" MIC MEM
and, to a lesser extent, for 1" MIC ERT; in contrast, 2" MIC
MEM showed an absence of growth at 24 h. When the double-
carbapenem combination was tested at concentrations of 1"
MICMEMþ 1"MIC ERT, 0.5"MICMEMþ 1"MIC ERT,
and 2"MIC MEM þ 1"MIC ERT, a bactericidal activity was
achieved at 4, 6, and 8 h and maintained up to 24 h with an
absence of bacterial growth (Figure 1B).
DISCUSSION
To our knowledge, this is the first report concerning a BSI
caused by a KPC-producer E coli in a renal transplant patient
treated with the double-carbapenem regimen, whose effective-
ness was demonstrated throughout in vitro analyses.
In the recent years, the spread of CRE has become of major
concern given that they show high levels of resistance to
antimicrobial classes other than carbapenems.2 Although sev-
eral mechanisms can lead to carbapenem resistance,3,15 much of
the increase in CRE has been caused by the spread of carba-
penemase-producing K pneumoniae, whereas the recent epide-
miological data regarding the emergence of severe infections
FIGURE 2. Timeline of clinical condition, interventions, and outcome. BAL ¼ bronchoalveolar lavage, TMP/SMX ¼ trimethoprim/
sulfamethoxazole, PO ¼ postoperative.
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caused by KPC-producing E coli16,17 suggested that horizontal
transfer of blaKPC genes among Enterobacteriaceae colonizing
the human intestine may occur.
In transplant recipients, the impact of infections caused by
MDR gram-negative bacteria, which generally occur in the first
postoperative month,11 is a matter of concern because of the high
mortality rates.18 Subjects could become colonized or infected
with MDR microorganisms before or after transplantation.19
Furthermore, therapeutic options are worryingly limited
since antimicrobials might exhibit toxicity and eventually inter-
act with immunosuppressive agents.11 In this challenging set-
ting, which seems to be even more complex due to the growing
rate of resistance to colistin in CRE,2 innovative approaches
including the double-carbapenem regimen have been proposed
as a valid therapeutic option in severe infections due to CR K
pneumoniae.6–9
In the present case, the strain showed in vitro sensitivity to
both colistin and aminoglycosides. However, although in the
presence of severe infections caused by resistant strains colistin-
induced nephrotoxicity does not represent a major concern with
a new formula of this drug, with regular monitoring of renal
function, and with adequate kidney-based dose adjustment and
hydration, the administration of these drugs was discouraged
because of their well-known potential nephrotoxicity, especi-
ally if used together. Thus, based on the recent reports con-
cerning the use of the double-carbapenem regimen,6,20 the
patient was regarded as eligible for this unconventional
therapeutic combination.
Despite high MICs to both ERT and MEM, our in vitro
study demonstrated that the combination ERT plus MEM
showed synergistic and bactericidal activity against a KPC-
producing E coli. In particular, the combination 0.5 " MIC
MEM þ 1 " MIC ERT resulted to be highly bactericidal
(Figure 1B), suggesting that even subinhibitory concentrations
of MEM (16mg/mL, which could be achieved in the serum after
high dose and prolonged infusion of MEM) could be sufficient
in order to exert its antibacterial activity.
The rationale of using the double-carbapenem regimen is
based on the high affinity of carbapenemases for ERT, which
binds to the hydrolytic enzymes and allows the other carbape-
nem to be effective.20 Furthermore, recent data support the
hypothesis that high dose of carbapenems might reach adequate
serum concentrations to achieve their pharmacokinetic target
even against bacteria producing carbapenemases.21 Although
higher concentration of MEM alone (2" MIC, 64mg/mL) had
in vitro bactericidal effect similar to that of 0.5"MIC MEM þ
1 " MIC ERT (Figure 1B), we could speculate that, after
high doses and prolonged infusion of MEM, the MEM con-
centrations achievable in the serum of patients are more likely
closer to 16mg/mL than to 64mg/mL,21 which correspond
to 0.5 " MIC MEM and 2 " MIC MEM in vitro
concentrations, respectively.
In the present case, the double-carbapenem regimen was
considered effective in view of both clinical and microbiolo-
gical early responses (defervescence and negativity of blood
and drainage cultures at 96 h, respectively). However, the
patient experienced a worse outcome due to a massive bleeding
at the level of surgical anastomosis.
The present report has some limitations. First, the inclusion
of MEM in the treatment of the infection caused by S
maltophilia and a pan-sensitive E coli might have contributed
to the subsequent development of carbapenem resistance.
Furthermore, although clinical outcomes with this regimen were
favorable resulting in a rapid clearance of bacteremia, the
patient died 9 days after the diagnosis for causes other than
uncontrolled infection. Therefore, assessment of medium-term
outcome and final definitive cure of the infection could not be
allowed. Another limitation could have been obtaining syner-
gistic antimicrobial in relation with the susceptibility profile of
MEM and ERT, regarding the possibility of using carbapenems
in cases with MIC values equal to or >32mg/mL. However,
throughout in vitro killing studies we were able to show how the
combination 0.5 " MIC MEM þ 1 " MIC ERT was bacteri-
cidal, supporting the hypothesis that ERT might have a promi-
nent role in the combination by binding to carbapenemases and
thus leading achievable serum concentration of MEM (ie,
16mg/mL) to be effective.6
In conclusion, the present study showed the effectiveness
of the double-carbapenem regimen in a transplant recipient with
BSI due to CR E coli. This unconventional approach might be
considered as a rescue therapy in those subjects, including
transplant recipients, in whom previous antimicrobial combi-
nations failed or when colistin use might be discouraged.
Furthermore, this case outlines that performing in vitro synergy
testing represents a useful strategy in order to select the best
antimicrobial combinations, especially in cases of infections
occurring in high-risk individuals such as transplant recipients.
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